Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

Fran Visco awarded the Presidential Citizens Medal: “We are not going to change what we do or how we do it.”

Credit for photos: White HouseIn 1992, 44-year old Philly trial lawyer and breast cancer survivor, Fran Visco, took the stand before the Senate Labor, HHS, Education Appropriations Subcommittee, asserting a tone and stance previously unfamiliar in the world of cancer groups asking for funding before Congress.

January 10, 2025

Vol.51 No.01

By Claire Marie Porter

Clinical Roundup

Elinzanetant meets all endpoints in phase III trial for vasomotor symptoms caused by breast cancer treatments

Elinzanetant successfully met the primary endpoints of the phase III trial OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with breast cancer or at high risk of developing breast cancer, demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (also known as hot flashes) from baseline to week four and 12 compared to placebo.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows

A retrospective cohort study in women with breast cancer suggests that low oral doses of minoxidil taken during or after cancer treatment appear to regrow hair in most patients without causing any serious heart-related side effects that require additional therapies or hospitalization.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Heart disease patients may face increased breast cancer risk, MD Anderson observational study finds

According to researchers from The University of Texas MD Anderson Cancer Center, patients diagnosed with late-stage or metastatic breast cancer have a statistically significant increased risk of pre-diagnosis cardiovascular disease compared to those with early-stage cancer at diagnosis.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

FDA granted accelerated approval to encorafenib (Braftovi) with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show

AstraZeneca and Merckannounced long-term results from the OlympiA phase III trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival for people with germline BRCA-mutated HER2-negative high-risk early breast cancer.

December 13, 2024

Vol.50 No.46

Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

YOU MAY BE INTERESTED IN

Fran Visco awarded the Presidential Citizens Medal: “We are not going to change what we do or how we do it.”

Elinzanetant meets all endpoints in phase III trial for vasomotor symptoms caused by breast cancer treatments

Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows

Heart disease patients may face increased breast cancer risk, MD Anderson observational study finds

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show

Renew today!

Subscriber content

Never miss an issue!

Login